Abstract
Antiphospholipid syndrome and pregnancy
Antiphospholipid syndrome (APS) is the association of antiphospholipid antibodies with thromboses and/or obstetric morbidity. Obstetric morbidity includes recurrent first trimester loss, stillbirth, intrauterine death, pre-eclampsia, premature birth and fetal growth restriction. Although current treatment regimens including aspirin and low-molecular weight heparin have improved pregnancy outcomes, 30% of affected women have pregnancy complications. Women with APS are therefore high-risk pregnancies who should be monitored in specialist centres according to international standards.
Antiphospholipid syndrome (APS) is the association of antiphospholipid antibodies with thromboses and/or obstetric morbidity. Obstetric morbidity includes recurrent first trimester loss, stillbirth, intrauterine death, pre-eclampsia, premature birth and fetal growth restriction. Although current treatment regimens including aspirin and low-molecular weight heparin have improved pregnancy outcomes, 30% of affected women have pregnancy complications. Women with APS are therefore high-risk pregnancies who should be monitored in specialist centres according to international standards.
Originalsprog | Dansk |
---|---|
Tidsskrift | Ugeskrift for Læger |
Vol/bind | 178 |
Udgave nummer | 12 |
Sider (fra-til) | 2-5 |
ISSN | 0041-5782 |
Status | Udgivet - 18. jan. 2016 |
Udgivet eksternt | Ja |